



***Corresponding author:** Regaieg N, Psychiatry A department, Hedi Chaker University Hospital Center, Sfax, Tunisia, Tel : +216 21 419 877 ; E-mail: nour.regaieg@gmail.com

Received: 28-May-2022, Manuscript No. jart-22-67120; **Editor assigned:** 30-May-2022, PreQC No. jart-22-67120 (PQ); **Reviewed:** 13-Jun-2022, QC No. jart-22-67120; **Revised:** 17-Jun-2022, Manuscript No. jart-22-67120 (R); **Published:** 24-Jun-2022, DOI: 10.4172/2155-6105.100474

Citation: Regaieg N, Sellami R, Masmoudi R, Hentati S, Feki I, et al. (2022) Cannabis Use and Psychopathology: Self-Esteem and Anxiodepressive Disorders. J Addict Res Ther 13: 474.

Copyright: © 2022 Regaieg N, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits

Citation: Regaieg N, Sellami R, Masmoudi R, Hentati S, Feki I, et al. (2022) Cannabis Use and Psychopathology: Self-Esteem and Anxiodepressive Disorders. *J Addict Res Ther* 13: 474.

objectives were to assess the level of dependence and self-esteem in subjects consulting at the detoxification center of Sfax for cannabis

More than a quarter of our patients, i.e. 10 subjects (26.3%), had a psychiatric history such as depression (2 cases; 5.3%), psychotic disorder induced by cannabis (4 cases; 10.5%) and psychopathic-type personality disorder (4 cases; 10.5%). The median age of onset of the disorders was 21 years (minimum=19, maximum=29).

One-third of the subjects (8 cases; 21.1%) had a history of psychiatric hospitalization at a median frequency of 1.5. The reasons for hospitalization were withdrawal treatment (2 cases; 5.3%), cannabis psychosis (4 cases; 10.5%) and SA (2 cases; 5.3%).

Among our patients, 10 subjects (26.3%) had already attempted suicide, once (8 cases; 21.1%), or 3 times (2 cases; 5.3%). In two subjects (5.3%), a SA would have occurred as a result of cannabis use.

As for criminal history, 12 participants (31.6%) had a history of arrest; once for 10 subjects (26.3%) and 4 times for 2 subjects (5.3%). On the other hand, 6 people (15.8%) had been imprisoned. The cause of this history was the use of cannabis in 14 cases (87.5% of these participants).

Discussion

Conclusion: In our series, the median age of onset of cannabis use was 17 years, with extremes ranging from 12 to 30 years.

The mode of consumption was in a group for 16 patients (41.1%), alone for 14 patients (36.8%), or both for the remaining 8 (21.1%).

The frequency of use in the last 6 months was most often daily (26 cases; 68.5%). The same number of patients (4 cases; 10.5%) described consumption once or twice a week, 3 or 4 times a week and once or twice a month.

The median amount consumed over the past 6 months was 4 joints/day, ranging from a low of 3 to a high of 10.

The longest median duration of abstinence was 1 month with a minimum of 0 and a maximum of 6 months.

Problematic cannabis use (CAST):

The distribution of scores according to the CAST scale showed that 36 users (94.7%) had problematic cannabis use at the time of the study.

The median HADS global score (HADS-G) was 19 with a minimum of 12 and a maximum of 33.

The median anxiety score on the HADS-A subscale was 12, with scores ranging from 5 to 17. Two-thirds of the subjects (24 cases; 63.2%) had a score greater than or equal to 11, defining symptomatic anxiety.

The median HADS-D subscale depression score was 7, with ranges of 3 and 19. Based on a depression threshold score of 11, 16 patients (42.1%) had symptomatic depression (Figure 1).

The mean self-esteem score (E) was 17.7 ± 7.8 . The distribution of scores showed that 14 patients (36.8%) had a score below the threshold value of 15, below which self-esteem is considered low.

Problematic cannabis use according to the CAST scale was statistically correlated with stress/anxiety-induced use ($p=0.009$), an anxiolytic-type desired effect ($p=0.001$), tobacco consumption ($p=0.021$), as well as a longer period of abstinence ($p=0.034$).

Psychopathology:

In our series, anxiety was significantly correlated with a sedative-like desired effect ($p = 0.005$). While depression was associated with an antidepressant-like desired effect ($p < 0.001$).

In our population, several complications of cannabis use were significantly associated with anxiety and depressive disorders (Table 3).

Among all substances used, anxiety was statistically correlated with ecstasy use. While depression was significantly associated with the consumption

Indeed, cannabis use, and particularly chronic cannabis use, is associated with increased rates of depression and anxiety [29-31], even when participants have no known history of mental illness [8,16,32-43]. This association has been confirmed by cross-sectional studies [44], hence the importance of looking for these disorders in subjects consulting for withdrawal [26, 44-47].

However, the figures found in our work differ from those found in other studies conducted on patients consulting for withdrawal. Thus, these consultants in France present, according to the HADS score, anxiety and depressive disorders in 59% and 28% of cases, respectively [26].

Depression and addictive disorder are two entities that seem to be closely related. According to Ehrenberg (1998), "addiction is a way to fight depression; it abrades conflicts through compulsive behavior. If depression is the story of an untraceable subject, addiction is the nostalgia of a lost subject" [34]. Indeed, we find very often in

Citation: Regaieg N, Sellami R, Masmoudi R, Hentati S, Feki I, et al. (2022) Cannabis Use and Psychopathology: Self-Esteem and Anxiodepressive Disorders. *J Addict Res Ther* 13: 474.

Several studies have reported a link between low self-esteem and the use of PAS, which may allow the individual to fit into certain social groups or help counteract the negative emotions generated by

4. Fayal R (2017) Revue des programmes nationaux de santé ciblant les adolescents et les jeunes. République Tunisienne, Ministère de la santé publique, Tunisia.
5. Gobbi G, Atkin T, Zytynski T, Wang S, Askari S, et al. (2019) Association of cannabis use in adolescence and risk of depression, anxiety, and suicidality in young adulthood: a systematic review and meta-analysis. *JAMA Psychiatry* 76: 426-434.
6. World Drug Report (2017)

- (2009) Self-esteem and resilience: the connection with risky behavior among adolescents. *Addict Behav* 34: 287-291.
48. Butler A, Patte KA, Ferro MA, Leatherdale ST (2019) Interrelationships among depression, anxiety, flourishing, and cannabis use in youth. *Addict Behav* 89: 206-210.
49. Guillon MS, Crocq MA (2004) Estime de soi à l'adolescence : revue de la littérature. *Neuropsychiatr Enfance Adolesc* 52: 30-36.
50. Gullo MJ, Matveeva M, Feeney GFX, Young RMcD, Connor JP (2017) Social cognitive predictors of treatment outcome in cannabis dependence. *Drug Alcohol Depend* 170: 74-81.
51. Dorard G, Bungener C, Corcos M, Berthoz S(2014) Estime de soi, coping, soutien social perçu et dépendance au cannabis chez l'adolescent et le jeune adulte. *L'Encéphale* 40: 255-262.